SYDNEY, Jan 6 (Reuters) - South Korean IT services provider LG CNS started bookbuilding on Monday to raise up to $817 million in an initial public offering (IPO), according to a term sheet ...

HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for ...

HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel ...

LG CNS 0035504.52%increase; green up pointing triangle, an information-technology services affiliate of conglomerate LG Group, made a weak debut in South Korea after the country’s biggest ...

CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial ...

CNS Pharmaceuticals' Berubicin trial for recurrent GBM did not show a significant survival benefit over Lomustine. The study reported no cardiotoxicity with Berubicin, unlike other anthracyclines ...